Literature DB >> 20851211

Liver disease in the HIV-infected individual.

Jennifer C Price1, Chloe L Thio.   

Abstract

Since the advent of effective antiretroviral therapy (ART) for human immunodeficiency virus-1 (HIV), there has been a substantial decrease in deaths related to acquired immunodeficiency syndrome (AIDS). However, in the ART era, liver disease is now the most common non-AIDS-related cause of death among HIV-infected patients, accounting for 14%-18% of all deaths in this population and almost half of deaths among hospitalized HIV-infected patients. Just as the burden of non-AIDS morbidity and mortality has changed in the ART era, the types of liver disease the clinician is likely to encounter among these patients have changed as well. This review will discuss the causes of liver disease in the HIV-infected population in the ART era, including chronic hepatitis C virus, chronic hepatitis B virus, medication-related hepatotoxicity, alcohol abuse, nonalcoholic fatty liver disease, and AIDS-related liver diseases.
Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20851211      PMCID: PMC2997131          DOI: 10.1016/j.cgh.2010.08.024

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  97 in total

1.  Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?

Authors:  Firouzé Bani-Sadr; Lise Denoeud; Patrice Morand; Françoise Lunel-Fabiani; Stanislas Pol; Patrice Cacoub; Christian Perronne; Fabrice Carrat
Journal:  J Acquir Immune Defic Syndr       Date:  2007-05-01       Impact factor: 3.731

2.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.

Authors:  Fabrice Carrat; Firouzé Bani-Sadr; Stanislas Pol; Eric Rosenthal; Françoise Lunel-Fabiani; Asmae Benzekri; Patrice Morand; Cécile Goujard; Gilles Pialoux; Lionel Piroth; Dominique Salmon-Céron; Claude Degott; Patrice Cacoub; Christian Perronne
Journal:  JAMA       Date:  2004-12-15       Impact factor: 56.272

3.  Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.

Authors:  Barbara H McGovern; Jeremy S Ditelberg; Lynn E Taylor; Rajesh T Gandhi; Katerina A Christopoulos; Stacey Chapman; Beth Schwartzapfel; Emily Rindler; Anne-Marie Fiorino; M Tauheed Zaman; Paul E Sax; Fiona Graeme-Cook; Patricia L Hibberd
Journal:  Clin Infect Dis       Date:  2006-06-22       Impact factor: 9.079

4.  Acquired immunodeficiency syndrome cholangiopathy: spectrum of disease.

Authors:  J P Cello
Journal:  Am J Med       Date:  1989-05       Impact factor: 4.965

5.  Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis.

Authors:  B Soto; A Sánchez-Quijano; L Rodrigo; J A del Olmo; M García-Bengoechea; J Hernández-Quero; C Rey; M A Abad; M Rodríguez; M Sales Gilabert; F González; P Mirón; A Caruz; F Relimpio; R Torronteras; M Leal; E Lissen
Journal:  J Hepatol       Date:  1997-01       Impact factor: 25.083

Review 6.  Hepatobiliary and pancreatic infections in AIDS: Part II.

Authors:  A P Keaveny; M S Karasik
Journal:  AIDS Patient Care STDS       Date:  1998-06       Impact factor: 5.078

7.  Vanishing bile duct syndrome in a patient with advanced AIDS.

Authors:  S Hindupur; M Yeung; P Shroff; J Fritz; N Kirmani
Journal:  HIV Med       Date:  2007-01       Impact factor: 3.180

8.  Reactivation of latent hepatitis B virus infection with HIV-related immunosuppression.

Authors:  S J Clark; S Creighton; M Horner; H M Smith; B Portmann; C Taylor; M E Cramp
Journal:  Int J STD AIDS       Date:  2006-01       Impact factor: 1.359

Review 9.  Pathology of AIDS-related liver disease.

Authors:  J H Lefkowitch
Journal:  Dig Dis       Date:  1994 Nov-Dec       Impact factor: 2.404

10.  Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.

Authors:  C Grunfeld; M Pang; W Doerrler; J K Shigenaga; P Jensen; K R Feingold
Journal:  J Clin Endocrinol Metab       Date:  1992-05       Impact factor: 5.958

View more
  72 in total

Review 1.  Mechanisms of alcohol-mediated hepatotoxicity in human-immunodeficiency-virus-infected patients.

Authors:  Gyongyi Szabo; Samir Zakhari
Journal:  World J Gastroenterol       Date:  2011-05-28       Impact factor: 5.742

2.  Causes of liver disease and its outcome in HIV-infected individuals.

Authors:  Suryanarayana Bettadpura Shamanna; Ramavath Raghu Ramulu Naik; Abdoul Hamide
Journal:  Indian J Gastroenterol       Date:  2016-07-20

Review 3.  Insights into human immunodeficiency virus-hepatitis B virus co-infection in India.

Authors:  Runu Chakravarty; Ananya Pal
Journal:  World J Virol       Date:  2015-08-12

4.  Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial.

Authors:  McNeil Ngongondo; Sachiko Miyahara; Michael D Hughes; Xin Sun; Gregory P Bisson; Amita Gupta; Johnstone Kumwenda; Jeffrey A Lavenberg; Thiago Silva Torres; Mulinda Nyirenda; Katende Kenneth Kidonge; Mina C Hosseinipour
Journal:  J Acquir Immune Defic Syndr       Date:  2018-05-01       Impact factor: 3.731

5.  Serum microRNAs in HIV-infected individuals as pre-diagnosis biomarkers for AIDS-NHL.

Authors:  Dharma R Thapa; Shehnaz K Hussain; Wen-Ching Tran; Gypsyamber Dʼsouza; Jay H Bream; Chad J Achenback; Velpandi Ayyavoo; Roger Detels; Otoniel Martínez-Maza
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

6.  Liver Function Tests Abnormalities and Hepatitis B Virus & Hepatitis C Virus Co-infection in Human Immunodeficiency Virus (HIV)-infected Patients in India.

Authors:  P Puri; P K Sharma; A Lolusare; V K Sashindran; S Shrivastava; A K Nagpal
Journal:  J Clin Exp Hepatol       Date:  2016-12-29

7.  Comorbidities associated with HIV and antiretroviral therapy (clinical sciences): a workshop report.

Authors:  L T Vernon; Plp Jayashantha; M M Chidzonga; M C Komesu; R G Nair; N W Johnson
Journal:  Oral Dis       Date:  2016-04       Impact factor: 3.511

8.  Acrolein enhances epigenetic modifications, FasL expression and hepatocyte toxicity induced by anti-HIV drug Zidovudine.

Authors:  Smita S Ghare; Hridgandh Donde; Wei-Yang Chen; David F Barker; Leila Gobejishvilli; Craig J McClain; Shirish S Barve; Swati Joshi-Barve
Journal:  Toxicol In Vitro       Date:  2016-05-26       Impact factor: 3.500

9.  Effects of combined alcohol and anti-HIV drugs on cellular stress responses in primary hepatocytes and hepatic stellate and kupffer cells.

Authors:  Jay Hu; Hui Han; Mo Yin Lau; Harrison Lee; Michelle MacVeigh-Aloni; Cheng Ji
Journal:  Alcohol Clin Exp Res       Date:  2015-01       Impact factor: 3.455

10.  Intentional non-adherence to medications among HIV positive alcohol drinkers: prospective study of interactive toxicity beliefs.

Authors:  Seth C Kalichman; Tamar Grebler; Christina M Amaral; Megan McNerey; Denise White; Moira O Kalichman; Chauncey Cherry; Lisa Eaton
Journal:  J Gen Intern Med       Date:  2012-10-12       Impact factor: 5.128

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.